Chromium 500microgram capsules
Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Chromium
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(6)
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (HTG287)
VEST external stent for coronary artery bypass grafts (MIB115)
Mobi-C for cervical disc replacement (MIB70)
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 29 studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 2023–2026
Showing all 29 studies, sorted by most relevant.
Babakr AT, Mukhtar MH, Ali ASE, et al.
2026
Metabolic syndrome (MetS) is a complex interplay of interrelated metabolic derangements, including insulin resistance, dyslipidemia, central adiposity, and hypertension, thereby markedly amplifying the predisposition to type 2 diabetes mellitus (T2DM) and cardiovascular morbidities. Chromium (Cr), an indispensable trace element, has garnered scientific interest for its putative role in augmenting insulin sensitivity and modulating glucose metabolism. Chromium deficiency has been linked with insulin resistance and diabetes mellitus. A cycle of low chromium, defective glucose metabolism, and further loss of chromium is documented. Chromium supplementation has been associated with encouraging improvements in insulin sensitivity. It may enhance insulin signaling, regulate lipid metabolism, and mitigate obesity-related dysfunctions. However, its therapeutic efficacy remains debated due to inconsistent clinical outcomes and study variations. This comprehensive review delves into the implications of chromium supplementation, particularly chromodulin, in the context of MetS and its associated pathological sequelae. In conclusion, chromium (Cr) enhances insulin sensitivity by directly activating the insulin receptor kinase, which lowers the required insulin concentration for maximal cellular response and improves glucose uptake and storage. Synthesis of the evidence shows that Chromium (Cr) supplementation significantly benefits individuals with chromium deficiency or diabetes, improving glucose homeostasis and insulin sensitivity. This highlights the importance of baseline metabolic status in the effectiveness of Cr as a treatment, indicating that targeted interventions may be needed for optimal results in those with metabolic disturbances.
Abstract licence: CC BY-NC
Ronald Chan, Jiaguan Zhang, Colman Mcgrath, et al.
European Oral Research, 2023
Purpose: This study aimed to assess the effectiveness of ultrasonic denture hygiene interventions in improving denture cleanliness among elderly individuals. Materials and methods: Sixty-six participants who had received upper metal framework removable partial dentures within the past 5 years were randomly allocated into three denture hygiene intervention groups: group 1 (mechanical cleaning with a toothbrush and ultrasonic cleaning with cetylpyridinium chloride), group 2 (mechanical cleaning with a toothbrush and ultrasonic cleaning with distilled water), and control (mechanical cleaning with a toothbrush only). Denture cleanliness was assessed at baseline and 1-month using: i) Denture Cleanliness Index (DCI) scores; ii) plaque coverage percentage; and (iii) microbiological samples for bacterial and yeast detection. Differences between groups were assessed with one-way analysis of variance and Chi-squared tests. Results: Mean DCI scores and mean percentages of plaque coverage area were significantly reduced in group 1 and group 2, compared to the control group for both cobalt chromium (CoCr) and acrylic fitting surfaces (p<0.001). No significant differences were found between groups 1 and 2 with regard to the prevalence and viable counts of yeasts or total microbial viable counts. No significant differences in the investigated clinical and microbiological parameters were observed between CoCr and acrylic surfaces following the intervention period. Conclusion: The ultrasonic cleaner was significantly more effective than mechanical cleaning in the reduction of biofilm coverage on metal framework removable partial dentures over a 1-month intervention period. Nevertheless, the adjunctive use of cetylpyridinium chloride with ultrasonic cleaning did not yield additional benefits.
Abstract licence: CC BY-NC-ND
Ju Xu, Mengke Liu, Guojun Ma, et al.
Metals, 2023
As a type of metallurgical solid waste with a significant output, chromium-containing metallurgical dust and slag are gaining increasing attention. They mainly include stainless steel dust, stainless steel slag, ferrochrome dust, and ferrochrome slag, which contain significant amounts of valuable elements, such as chromium, iron, and zinc, as well as large amounts of toxic substances, such as hexavalent chromium. Achieving the harmless and resourceful comprehensive utilization of chromium-containing metallurgical dust and slag is of great significance to ensuring environmental safety and the sustainable development of resources. This paper outlines the physicochemical properties of stainless steel dust, stainless steel slag, ferrochrome dust, and ferrochrome slag. The current treatment technologies of chromium-containing metallurgical dust and slag by hydrometallurgy, the pyrometallurgical process, and the stabilization/solidification process are introduced. Moreover, the comprehensive utilization of resources of chromium-containing metallurgical dust and slag in the preparation processes of construction materials, glass ceramics, and refractories is elaborated. The aim of this paper is to provide guidance for exploring effective technology to solve the problem of chromium-containing metallurgical dust and slag.
Abstract licence: CC BY
Wang B, Gao J, Wang F, et al.
2026
Chromium slag, a chromium-bearing solid waste characterized by substantial environmental hazards yet with appreciable resource potential, has become a focal topic in solid-waste pollution control and the circular economy. Centered on the overarching logic of "evidence chain-system boundary-scalable and verifiable acceptance," this review systematically synthesizes recovery technologies, industrial-scale utilization pathways, and the key challenges associated with the detoxification and resource utilization of chromium slag. From the perspective of recovery technologies, we examine pyrometallurgical and hydrometallurgical routes, solidification/stabilization (S/S), and bioelectrochemical coupling approaches, elucidating their fundamental principles, applicability boundaries, and critical nodes where environmental burdens may be transferred across media. We emphasize that process design should concurrently consider detoxification efficiency, resource recovery performance, and whole-process pollution control. Regarding utilization pathways, this review highlights three major routes with strong scale-up relevance-metallurgical process co-treatment (CAP-sintering-blast furnace), bulk utilization in construction materials, and high-value utilization-and analyzes their industrial potential and engineering constraints. Particular attention is given to the lack of long-term leaching and durability evidence, which represents a central bottleneck limiting product-side credibility. Furthermore, we discuss cross-cutting challenges including the long-term stabilization of Cr(VI), the verifiability of "green utilization" concepts, cost and economic feasibility, and standardized acceptance criteria. We propose that future research should shift from single-process optimization toward multi-objective, system-level evaluation, and establish a full-chain evidence system covering "speciation/mineral phases-process mechanisms-environmental behavior-risk assessment-engineering scale-up-standardized acceptance." This review aims to provide a systematic analytical framework and practical reference for improving comparability across resource-utilization technologies and supporting engineering decision-making for chromium slag management.
Abstract licence: CC BY
V. I. Kryukov, S. A. Zhuchkov, T. N. Lazareva, et al.
Учёные записки Казанского университета: Серия Естественные науки, 2023
This article reports the results of a study of Cr(VI) ions mutagenicity in the erythrocytes of Bufo viridis tadpoles under the influence of a low-frequency pulsed magnetic field (LF PMF). The tadpoles were randomly divided into 14 groups ( n = 7). One group of intact tadpoles served as control. Other groups were experimental. The first six groups were placed for 24 h in water containing Cr(VI) at different concentrations (0.025, 0.05, 0.125, 0.25, 0.375, and 0.50 mg/L). The eighth group was subjected to an 8-h exposure to LF PMF (41 mT, 16 Hz). The remaining six groups of tadpoles were kept for 24 h in water with Cr(VI) ions at the specified concentrations and were also irradiated with LF PMF (41 mT, 16 Hz) during the first 8 h of this period. A day after the exposure, blood smears were taken, and the frequencies of micronuclei and nuclear anomalies in erythrocytes were analyzed. The results reveal that low concentrations of Cr(VI) (0.025 and 0.05 mg/L), unlike the higher ones (0.125 mg/L and above), did not significantly affect the frequencies of the analyzed anomalies. The combined action of Cr(VI) and LF PMF significantly increased the frequencies of the recorded anomalies in all the six variants of the experiment. The synergistic effect of Cr(VI) and LF PTF was shown.
Abstract licence: CC BY
Inés Pérez-Gonzalo, Florentino Alvarez-Antolin, Alejandro González-Pociño, et al.
Journal of Manufacturing and Materials Processing, 2025
This study investigates the mechanical, tribological, and electrochemical behaviour of a novel precipitation-hardenable martensitic alloy produced by selective laser melting (SLM). The alloy was specifically engineered with an optimised composition, free from cobalt and molybdenum, and featuring reduced nickel content (7 wt.%) and 8 wt.% chromium. It has been developed as a cost-effective and sustainable alternative to conventional maraging steels, while maintaining high mechanical strength and a refined microstructure tailored to the steep thermal gradients inherent to the SLM process. Several ageing heat treatments were assessed to evaluate their influence on microstructure, hardness, tensile strength, retained austenite content, dislocation density, as well as wear behaviour (pin-on-disc test) and corrosion resistance (polarisation curves in 3.5%NaCl). The results indicate that ageing at 540 °C for 2 h offers an optimal combination of hardness (550–560 HV), tensile strength (~1700 MPa), microstructural stability, and wear resistance, with a 90% improvement compared to the as-built condition. In contrast, ageing at 600 °C for 1 h enhances ductility and corrosion resistance (Rp = 462.2 kΩ; Ecorr = –111.8 mV), at the expense of a higher fraction of reverted austenite (~34%) and reduced hardness (450 HV). This study demonstrates that the mechanical, surface, and electrochemical performance of this novel SLM-produced alloy can be effectively tailored through controlled thermal treatments, offering promising opportunities for demanding applications requiring a customised balance of strength, durability, and corrosion behaviour.
Abstract licence: CC BY
Chunzhi Xia, Yinggang Liu, Xiaoguo Song, et al.
Materials Research, 2023
The laser welded joint of 2000MPa cold rolled annealed hot pressed steel (PHS) is easy to break during cold rolling. In this paper, the laser welding method is used to butt weld four kinds of PHS2000 with a thickness of 3.5mm. The four kinds of PHS2000 steel are added with elements of 0% Nb, 0.04% Nb, 0.06% Nb + Cr and 0.08% Nb + Cr. The microstructure of the four kinds of welded joints is compared and analyzed. The mechanical properties of the four kinds of joints are compared through hardness test and tensile test. The results show that after adding 0.04% Nb, residual austenite appears in the weld zone and fully quenched zone, the width of columnar crystal decreases, the average hardness of the weld zone decreases from 595HV to 408HV, and the tensile strength increases from 608MPa to more than 800MPa. For chromium containing steel, the increase of niobium content can reduce the size of columnar crystal in weld zone.
Abstract licence: CC BY
Karima Ezziane, Mayouf Sellami, Mostefa Kameche, et al.
Cerâmica, 2024
Abstract New limited pyrochlore solid solutions of formula Bi1.5-xMxSb1.5-xM'xZnO7 (M= Fe; M'=Fe, Cr) (x=0; 0.10; 0.15) are prepared from simple oxides at 1080°C by using the ceramic method. All the crystal phases are indexed in the cubic system (space group; No.227). Rietveld refinement method of the Bi1.5Sb1.5ZnO7 (x=0) compounds using powder XRD analysis confirms an overall A2B2O7 cubic pyrochlore structure according to B i 1 . 5 3 + Z n 0 . 5 2 + S b 1 . 5 5 + Z n 0 . 5 2 + O 7 formula with 10.44425(3) Å and F d 3 ¯ m space group. The substitution of Bi(III) and Sb(V) by Fe(III) and Cr(III) in the Bi1.5Sb1.5ZnO7 phase shows the appearance of solid solutions limited to x=0.15. The variation of the cell’s parameter is recorded to the element’s ionic radii. The paramagnetic character is observed in all substituted compounds. The measurements of the electrical conductivity as a function of the temperature, make evidence of the semi-conductive property. Whilst, the magnetic susceptibility satisfies the modified Curie Weiss (CW) and shows the magnetic behavior due to the magnetic moments of the iron and chromium ions being involved in the synthesis of the compounds. Besides, the UV-Visible reflectance displays light absorption in the visible domain.
Abstract licence: CC BY
Esra Bilgi-Ozyetim, Gökçen Dinçer, Ammar Sulaiman, et al.
BMC Oral Health, 2025
- Dental Abutments
- Dental Implants
- Dental Implant-Abutment Design
BACKGROUND: This study aims to evaluate the stress distribution in peri-implant bone, implant surfaces, and within the framework material under vertical and oblique loads, considering various angulations and abutment types of bendable one-piece implants in the All-on-4 concept. METHODS: A three-dimensional model of an edentulous mandible was constructed. Six different configurations were modeled according to prosthesis connection type and inclination of the posterior implants based on the All-on-4 protocol. Four one-piece implants were placed in each model and a cobalt-chromium frameworks with 14 mm cantilever lengths were designed. Under vertical and oblique loading conditions, maximum principal stress and minimum principal stress values were obtained for cortical and trabecular bone and von Mises stress values were calculated for implants and frameworks. RESULTS: Implant angulation, connection type, and loading conditions affected stress distribution in the peri-implant bone, implants, and frameworks. Higher stress values were observed in posterior implants with increased angulation. Screw-retained models demonstrated greater stress values compared to cement-retained ones under both loading conditions. CONCLUSIONS: For optimal stress distribution in peri-implant bone and frameworks, cement-retained prosthesis may be preferred, especially in cases with increased implant angulation in one-piece bendable systems. Additionally, careful consideration of posterior implant angulation and loading conditions is crucial to minimize the excessive stress and to enhance long-term stability. CLINICAL TRIAL NUMBER: Not applicable.
Abstract licence: CC BY
Priyanka Aggarwal, Pallavi Anand, Kopal Singh, et al.
Journal of Indian Society of Pedodontics and Preventive Dentistry, 2023
- Dental Caries
- Gallium
- Lasers, Solid-State
Background: Well articulated by John Knowles - "Everything has to evolve or else it perishes." With the paradigm shift of emphasis toward the prevention of dental caries, it has been proven that laser irradiation protects against both caries initiation and caries progression. Aim: The aim of the study was to evaluate and compare the micromorphology of caries-free extracted premolars using a Scanning electron microscope (SEM) after fissurotomy by conventional fissurotomy bur and erbium, chromium: yttrium, scandium, gallium, and garnet (ER, CR: YSGG) hard-tissue laser. Methodology: Sixty caries-free premolars extracted atraumatically for orthodontic treatment were included in the study. The samples were divided into two groups randomly (Group 1: fissurotomy by bur, n = 30, and Group 2: fissurotomy by hard-tissue laser, n = 30). Each sample was further divided into halves from the occlusal surface wherein one-half of the occlusal surface received fissurotomy procedure and the other half was control. Samples were analyzed by scanning electron microscopy (SEM) for micromorphological changes. Results: Profile image of control samples revealed the disorganization of enamel surface at the junction of fissures forming a heterogeneous tissue and agglomeration of enamel with deep pit and fissure. On the contrary, the image of experimented samples (with laser fissurotomy) showed smooth enamel surface and homogeneous enamel subsurface with wider pit and fissure owing to self-cleansing ability. Conclusion: On the grounds of the present study results, it could be concluded that the intervention of ER, CR: YSGG hard-tissue laser possesses self-cleansable pit and fissures for caries prevention and has the potential to irradicate the smear layer entirely for superior attachment of remineralizing agents.
Abstract licence: CC BY-NC-SA
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
15 to 41 hours
Mechanism
Chromium is an essential nutrient involved in the metabolism of glucose, insulin and blood lipids.
Food interactions
2 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.5%
Half-life
15 to 41 hours
[L1982]
Protein binding
95%
[L1983]…
Volume of distribution
[L1990]…
Metabolism
Elimination
80%
[L1982]…
Clearance
3 to 50 μg/d
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
According to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 μg and 25 μg, respectively [L1986]. Chromium picolinate capsules may be used as nutritional adjuvant in patients with or at risk of type 2 diabetes mellitus (T2DM) to improve blood sugar metabolism and stabilize the levels of serum cholesterol. Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 718 interactions
[L1982]
Oral LD50 for Cr (III) in rat is >2000 mg/kg .
[L1982]
LD50 of chromium (III) oxide in rats is reported to be > 5g/kg .
[L1983]
Other LD50 values reported for rats include: 3.5 g/kg (CI 3.19-3.79 g/kg) for chromium sulphate; 11.3 g/kg for chromium (III) acetate; 3.3 g/kg for chromium nitrate; and 1.5 g/kg for chromium nitrate nonahydrate .
[L1983]
Acute overdose of chromium is rare and seriously detrimental effects of hexavalent chromium are primarily the result of chronic low-level exposure .
[L1982]
In case of overdose with minimal toxicity following acute ingestion, treatment should be symptomatic and supportive .
[L1982]
There is no known antidote for chromium toxicity.
Hexavalent chromium is a Class A carcinogen by the inhalation route of exposure and Class D by the oral route .
[L1982]
The oral lethal dose in humans has been estimated to be 1-3 g of Cr (VI); oral toxicity most likely involves gastrointestinal bleeding rather than systemic toxicity .
[L1982]
Chronic exposure may cause damage to the following organs: kidneys, lungs, liver, upper respiratory tract MSDS. Soluble chromium VI compounds are human carcinogens. Hexavalent chromium compounds were mutagenic in bacteria assays and caused chromosome aberrations in mammalian cells.
There have been associations of increased frequencies of chromosome aberrations in lymphocytes from chromate production workers .
[L1981]
In human cells in vitro, Cr (VI) caused chromosomal aberrations, sister chromatid exchanges and oxidative DNA damage .
[L1982]
Under insulin-resistant conditions, chromium also promotes GLUT-4 transporter translocation that is independent of activity of IR, IRS-1, PI3-kinase, or Akt; chromium mediates cholesterol efflux from the membranes via increasing fluidity of the membrane by decreasing the membrane cholesterol and upregulation of sterol regulatory element-binding protein [A32353]. As a result, intracellular GLUT-4 transporters are stimulated to translocate from intracellular to the plasma membrane, leading to enhanced glucose uptake in muscle cells [L1990]. Chromium attenuates the activity of PTP-1B in vitro, which is a negative regulator of insulin signaling. It also alleviates ER stress that is observed to be elevated the suppression of insulin signaling. ER stress is thought to activate c-Jun N-terminal kinase (JNK), which subsequently induces serine phosphorylation of IRS and aberration of insulin signalling [A32353]. Transient upregulation of AMPK by chromium also leads to increased glucose uptake [A32353].
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L1982]
Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed .
[L1986]
Vitamin C and the vitamin B niacin is reported to enhance chromium absorption .
[L1986]
Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids .
[L1982]
Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration .
[L1982]
Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins.
Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF).
[L1982]
[L1983]
Serum chromium is bound to transferrin in the beta globulin fraction [FDA Label].
[L1990]
Circulating Cr (III) following oral or parenteral administration of different compounds can be taken up by tissues and accumulates in the liver, kidney, spleen, soft tissue, and bone .
[L1986]
[L1983]
The metabolites bind to cellular constituents .
[L1982]
[L1982]
Chromium is excreted primarily in the urine by glomerular filtration or bound to a low molecular-weight organic transporter .
[L1990]
[L1990]
Proteins and enzymes this drug interacts with in the body
Proteins that carry this drug through the body
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Chromium
Additional database identifiers
Drugs Product Database (DPD)
2001
ChemSpider
22412
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2570
GenAtlas
CYB5A
GeneCards
CYB5A
GenBank Gene Database
M22865
GenBank Protein Database
181227
UniProt Accession
CYB5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11740
GenAtlas
TF
GeneCards
TF
GenBank Gene Database
M12530
GenBank Protein Database
339453
UniProt Accession
TRFE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure

Linked open data from Wikidata (Q725), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.